These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 10383558)
61. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069 [TBL] [Abstract][Full Text] [Related]
62. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Wu D; Kang YS; Bickel U; Pardridge WM Drug Metab Dispos; 1997 Jun; 25(6):768-71. PubMed ID: 9193881 [TBL] [Abstract][Full Text] [Related]
63. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Skarke C; Langer M; Jarrar M; Schmidt H; Geisslinger G; Lötsch J Anesthesiology; 2004 Dec; 101(6):1394-9. PubMed ID: 15564947 [TBL] [Abstract][Full Text] [Related]
64. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Lötsch J; Weiss M; Ahne G; Kobal G; Geisslinger G Anesthesiology; 1999 Apr; 90(4):1026-38. PubMed ID: 10201674 [TBL] [Abstract][Full Text] [Related]
65. Systematic review of factors affecting the ratios of morphine and its major metabolites. Faura CC; Collins SL; Moore AR; McQuay HJ Pain; 1998 Jan; 74(1):43-53. PubMed ID: 9514559 [TBL] [Abstract][Full Text] [Related]
66. Preliminary study of the pharmacokinetics, tissue distribution, and behavioral and select physiological effects of morphine 6-glucuronide (M6G) following intravenous administration to horses. Hamamoto-Hardman BD; Steffey EP; Seminoff K; McKemie DS; Kass P; Knych HK Can J Vet Res; 2022 Jul; 86(3):172-180. PubMed ID: 35794968 [TBL] [Abstract][Full Text] [Related]
67. Limited phase I study of morphine-3-glucuronide. Penson RT; Joel SP; Clark S; Gloyne A; Slevin ML J Pharm Sci; 2001 Nov; 90(11):1810-6. PubMed ID: 11745739 [TBL] [Abstract][Full Text] [Related]
68. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868 [TBL] [Abstract][Full Text] [Related]
69. Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Sear JW; Hand CW; Moore RA; McQuay HJ Br J Anaesth; 1989 Jan; 62(1):28-32. PubMed ID: 2644963 [TBL] [Abstract][Full Text] [Related]
70. Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. Dale O; Thoner J; Nilsen T; Tveita T; Borchgrevink PC; Klepstad P Eur J Clin Pharmacol; 2007 Sep; 63(9):837-42. PubMed ID: 17619868 [TBL] [Abstract][Full Text] [Related]
71. Oral morphine in cancer pain: influences on morphine and metabolite concentration. McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122 [TBL] [Abstract][Full Text] [Related]
73. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. D'Honneur G; Gilton A; Sandouk P; Scherrmann JM; Duvaldestin P Anesthesiology; 1994 Jul; 81(1):87-93. PubMed ID: 8042814 [TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. Handal M; Grung M; Skurtveit S; Ripel A; Mørland J Pharmacol Biochem Behav; 2002 Nov; 73(4):883-92. PubMed ID: 12213535 [TBL] [Abstract][Full Text] [Related]
75. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved? Faura CC; Olaso JM; Cabanes CG; Horga JF Pain; 1996 Apr; 65(1):25-30. PubMed ID: 8826486 [TBL] [Abstract][Full Text] [Related]
76. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. Ashby M; Fleming B; Wood M; Somogyi A J Pain Symptom Manage; 1997 Sep; 14(3):157-67. PubMed ID: 9291702 [TBL] [Abstract][Full Text] [Related]
77. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling. Bouw MR; Xie R; Tunblad K; Hammarlund-Udenaes M Br J Pharmacol; 2001 Dec; 134(8):1796-804. PubMed ID: 11739257 [TBL] [Abstract][Full Text] [Related]
78. Arterial and venous pharmacokinetics of morphine-6-glucuronide and impact of sample site on pharmacodynamic parameter estimates. Olofsen E; Mooren R; van Dorp E; Aarts L; Smith T; den Hartigh J; Dahan A; Sarton E Anesth Analg; 2010 Sep; 111(3):626-32. PubMed ID: 20547824 [TBL] [Abstract][Full Text] [Related]